Monday, November 2, 1998
A compound in Phase I testing for cancer anti-angiogenesis shows
exceptional promise as an all-around healer, allowing paralyzed mice to walk again.
CarboMed Inc. (Nashville, Tenn.) has licensed the agent to Zeneca Group plc (London, U.K.)
for cancer, but has retained the right to use the agent in other settings, such as acute
CM101, a polysaccharide isolated from group B streptococcus, is the
agent responsible for neonatal lung injury and death from